
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Remove Manufacturing filter Manufacturing (1)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA) (2)
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA)
- (-) Remove Complementary medicines filter Complementary medicines
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Manufacturing filter Manufacturing
Proposed update to the evidence guidelines for listed medicines
Closed on 1 April 2022
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021
Proposal for clarifying regulatory requirements for residual claims for disinfectants
Closed on 26 March 2021
Fees and charges proposal 2021-22
Closed on 17 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021